Live Breaking News & Updates on Mtm

Stay informed with the latest breaking news from Mtm on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mtm and stay connected to the pulse of your community

Contributor: Preparing for Massive MTM Program Expansion—Pharmacy-Led Medical Cost Savings to Fund CMS Changes

Changes in the medication therapy management (MTM) program willl require planning on how to best fund this program in a way that drives medical cost savings.

Medicare-advantage , Star-ratings , Mtm , Medicare , Cost-saving ,

Bank bonds: India's re-jig of banks' investment rules to boost govt debt appetite

The Reserve Bank of India (RBI) has removed the cap on how much banks can invest in bonds they intend to hold to maturity. This move is expected to increase their appetite for government securities and benefit their bottom lines. Government bonds are the most common form of investment in this category. The removal of the cap will also reduce earnings volatility and drive mark-to-market gains for lenders.

India , Prakhar-sharma , Reserve-bank , Bank-bonds , Mtm , Rbi , Htm , Government-debt , Reserve-bank-of-india ,

Macular Thickness Maps Effective Tools in Remote Monitoring of eAMD

Recurrent exudations in patients with exudative age-related macular degeneration (eAMD) can be sufficiently monitored with macular thickness maps alone.

United-states , American , Bascom-palmer-eye-institute , American-journal , Bascom-palmer-eye , Mtm , Eamd , Macular-thickness-maps , Oct ,

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months ABERDEEN, Scotland and SINGAPORE, Dec. 1, 2022 /PRNewswire/ --TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. As a hallmark of the disease, it is recognised as a key target for disease modifying treatments. This approach by TauRx contrasts to many in the field, where the focus has largely been on the role of beta-amyloid. Experts in the field are increasingly looking at alternative therapeutic approaches to find a breakthrough treatment that offers clinically meaningful benefit, ease of administration and low burden of care associated with a reassuring safety profile. Supporting a path to regulatory submissions, the most recent data from LUCIDITY shows sustained improvement in cognition over 18 months over pre-treatment levels in those participants with MCI due to AD, building on previous data shared in October 2022. This treatment effect was seen only at the 16 mg/day dose of HMTM. Sustained cognitive improvement over baseline has not been seen with any other late-stage treatment for Alzheimer's currently being studied. Coupled with the strong safety profile, convenient oral administration, and lack of need for more than routine clinical monitoring, this positions HMTM as a game-changing prospect for the future treatment of this global unmet need. On hearing the data and explanations for the path forward from TauRx, Dr George Grossberg, Professor, Director Division of Geriatric Psychiatry Department of Psychiatry & Behavioural Neuroscience, St Louis University School of Medicine, commented, "It is encouraging to see data on a potential disease modifying therapy focusing on the role of Tau in Alzheimer's disease. Being an oral agent with a good safety profile is another advance in the disease-modifying arena for Alzheimer's disease." TauRx will announce further data on completion of the 24-month study in mid-2023, with additional blood-based biomarker data commissioned to be available early next year. Meanwhile, TauRx is preparing for regulatory submissions primarily in the UK, US, and Canada, with other key territories on their target list, including China, to follow alongside additional studies. The recent announcement of additional investment of USD119 millionthrough a warrants exercise triggered by the study results allows the company to move forward with regulatory submissions and preparation for market availability. ABOUT LUCIDITY LUCIDITY is the only late-stage clinical trial specifically targeting the tau pathology of Alzheimer's. Aggregation of abnormal tau protein is one of the hallmark pathologies. Additional data analysis is ongoing in relation to the 1-year open label phase of the trial, secondary endpoints including MRI volumetric brain scans, and exploratory endpoints. A summary of the LUCIDITY study protocol has recently been published in The Journal of Prevention of Alzheimer's Disease http://dx.doi.org/10.14283/jpad.2022.63). https://www.luciditytrial.com ABOUT TAURx PHARMACEUTICALS LTD The TauRx group of companies was established in 2002 in Singapore, continuing a partnership with the University of Aberdeen, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases due to protein aggregation pathology. Alzheimer's dementia is a leading cause of death throughout the world and one of the most important public health issues to be addressed globally. TauRx will contribute to addressing this unmet need with data from LUCIDITY and pursuit of regulatory approvals in line with its overall plans to commercialise HMTM and pursue clinical trials in other related neurodegenerative diseases. https://www.taurx.com TAU PATHOLOGY IN ALZHEIMER'S Through dedicated research programs, it is understood that certain age-related factors lead to misfolding and aggregation of tau proteins, and the subsequent formation of tau tangles in Alzheimer's. These tangles disrupt and damage neuronal function, a process that begins many years before symptoms of dementia are seen. Tau pathology has been proven to correlate with the clinical decline (loss of memory and ability to care for oneself) commonly seen in people with Alzheimer's, establishing it as an important target for treatment. HMTM is a tau aggregation inhibitor, which effectively crosses the blood brain barrier to target the source of this damaging process.

China , Canada , United-kingdom , Singapore , San-francisco , California , United-states , Scotland , George-grossberg , St-louis-university-school-of-medicine , University-of-aberdeen , Taurx-pharmaceuticals-ltd

TauRx Pharmaceuticals Ltd: LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY

China , Canada , United-kingdom , Singapore , San-francisco , California , United-states , Scotland , Kostenloser-wertpapierhandel , George-grossberg , Prnewswire-taurx-pharmaceuticals-ltd , St-louis-university-school-of-medicine

MTM to Begin Operating $50 Million Missouri NEMT Program

LAKE SAINT LOUIS, Mo., Nov. 29, 2022 (GLOBE NEWSWIRE) -- MTM is pleased to announce that it will begin operating the statewide Missouri Non-Emergency...

Missouri , United-states , District-of-columbia , Missourians , Ashley-wright , Alaina-macia , Department-of-mental-health , Missouri-non-emergency-medical-transportation , Social-services , Net-division , Mental-health , Net-managed-care-organizations

Vice President of Government Sales Michael Hammond Joins

LAKE SAINT LOUIS, Mo., Nov. 01, 2022 (GLOBE NEWSWIRE) -- As part of the organization's ongoing efforts to align its non-emergency medical transportation...

United-states , District-of-columbia , Ashley-wright , Dave-busch , United-states-department-of-health , College-for-behavioral-health-leadership , Mental-health-services-administration , Human-services , United-health-group , Public-affairs , Department-of-health , Baker-university

MTM Transit Expands Partnership With the Salem Area Mass

LAKE SAINT LOUIS, Mo., Oct. 06, 2022 (GLOBE NEWSWIRE) -- MTM Transit is pleased to announce that it is expanding its presence in the Salem, Oregon, area...

Salem , Oregon , United-states , Americans , Brian-balogh , Scott-transue , Ashley-wright , Regional-service , Cherriots-regional-service , Salem-area-mass-transit-district , Disabilities-act , Regional-vice-president-scott

MTM, Inc. Announces Major Acquisition of Veyo

The companies plan to transform the NEMT industry as a joint organization...

District-of-columbia , United-states , California , San-diego , Missouri , Jessica-williams , Greenburg-taurig , Josh-komenda , Alaina-macia , Wells-fargo-securities , Jp-morgan , Mtm-inc

TauRx Pharmaceuticals Ltd: Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial

LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published researchSafety profile

Malaysia , United-kingdom , Singapore , Kostenloser-wertpapierhandel , Claude-wischik , Genting-taurx-diagnostic-centre-sdn-bhd , Gt-diagnostics-united-kingdom , Global-conference-of-alzheimer-disease-international , University-of-aberdeen , Taurx-pharmaceuticals-ltd-group , Regulatory-agency , Genting-berhad